AstraZeneca triple therapy Breztri Aerosphere gets MHLW approval for listing

COPD is an ongoing disease that can cause obstruction of air flow in the lungs and lead to degenerative breathing difficultiesIt affects the lives of 384 million people worldwide and is expected to be the world's third leading cause of death by 2020today, AstraZeneca(http:// announcedthat its triple therapy Breztri Aerosphere (formerly known as PT010) has been approved by Japan's Ministry of Health, Labour and Welfare (MHLW) to relieve symptoms of chronic obstructive pulmonary disease (COPD)about Breztri AerosphereBreztri Aerosphere is a triple therapy consisting of three active ingredients, Budinide, Gromon Ammonium, and Fumotro, which is delivered using Aerosphere delivery technologyThis is the first time this triple therapy has been approved worldwide
Breztri Aerosphere, also known as PT010, is a fixed formula-combination combination therapy consisting of Boudinaid (inhaled corticosteroids), gramobromonised an niobium bromide (long-acting toxalynigraan agonist), and Fumotero (long-acting beta2 receptor agonist)It uses Aerosphere delivery technology and can be used in an inhalerThis approval is based on the positive results of Breztri Aerosphere'sin the phase 3 clinicaltrial
(http:// called KRONOSin this randomized double-blind phase 3 trial involving 1,900 patients with severe COPD, Breztri Aerosphere significantly improved lung function in patients compared to the double therapy Bevespi Aerosphere or PT009The results of this trial have been published in The Lancet Thaly Medicine